Acquisition strengthens Bayer’s drug discovery capabilities with cutting-edge chemoproteomics platform Vividion’s unique approach identifies previously unknown binding pockets in undruggable targets to generate first-in-class novel compounds in indications of high unmet medical need Vividion’s technology has already proven its applicability pre-clinically in oncology and immune-related diseases, with potential to expand into additional therapeutic areas Vividion …
Nuvalent Completes $135 Million Series B Financing to Advance Portfolio of Novel Precisely Targeted Kinase Inhibitors for Treatment-Resistant Cancers
CAMBRIDGE, Mass., May 11, 2021 /PRNewswire/ — Nuvalent, Inc., a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the completion of a $135 million Series B financing. The round was led by Bain Capital Life Sciences with participation from sole founding investor, Deerfield Management, and additional new investors …
Scribe Therapeutics Raises $100M Series B Financing to Further Develop “CRISPR by Design” Platform and Pipeline of Breakthrough Genetic Medicines
Molecular engineering company’s fully integrated evergreen platform accelerates the development of best-in-class in vivo therapies that treat the underlying cause of disease March 31, 2021 10:00 AM Eastern Daylight Time ALAMEDA, Calif.–(BUSINESS WIRE)–Scribe Therapeutics Inc., a molecular engineering company creating the most advanced technologies for CRISPR-based genetic medicine, today announced the completion of an oversubscribed …
Monte Rosa Therapeutics Announces $95 Million Series C Financing to Accelerate Next-generation Protein Degradation Platform
March 12, 2021 07:00 AM Eastern Standard Time BOSTON–(BUSINESS WIRE)–Monte Rosa Therapeutics, a biotechnology company focused on discovering and developing precision medicines that degrade disease-causing proteins, announced today the closing of a $95 million Series C financing. The proceeds will be used to advance its lead development candidate into the clinic, accelerate pipeline growth and …
Vividion Announces $135 Million Series C Financing to Fuel Broad Pipeline of Precision Oncology and Immunology Programs
Proceeds to support advancement of the company’s unique discovery platform and robust portfolio of programs focused on high value, traditionally undruggable targets February 24, 2021 08:00 AM Eastern Standard Time SAN DIEGO–(BUSINESS WIRE)–Vividion Therapeutics, Inc., a biotechnology company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers …
+1 212.937.4970
info@avorocapital.com